Healix

Application of Bayesian Modeling with Infliximab to Determine Optimal Patient Specific Regimen

Authors:
Timothy E. Ritter, MD – Texas Digestive Disease Consultants, Southlake, TX, U.S.

Harry E. Sarles, MD – DHAT Research Institute, Garland, TX, U.S.

Robert C. McLeay, PhD – DoseMeRx, Brisbane, Australia

Lucinda J. Van Anglen, PharmD – Healix LLC, Sugar Land, TX, U.S.

Claudia P. Schroeder, PharmD, PhD – Healix LLC, Sugar Land, TX, U.S.

View Poster

View All

Phase II and Phase III Studies

Healix regularly and actively supports Phase II and Phase III clinical trials in each of our specialty areas, including active studies in Multiple Sclerosis and Intestinal Bowel Disease.

For information on partnering with Healix on a study, please contact us.

FacebookTwitterLinkedInarrow1arcsearchiconowdtnotfound